Kyverna Therapeutics (KYTX) Competitors $6.40 -0.27 (-4.05%) Closing price 04:00 PM EasternExtended Trading$6.32 -0.08 (-1.23%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. DNTH, UPB, AMPH, LENZ, PRAX, SPRY, RLAY, SEPN, SANA, and COLLShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Dianthus Therapeutics (DNTH), Upstream Bio (UPB), Amphastar Pharmaceuticals (AMPH), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), ARS Pharmaceuticals (SPRY), Relay Therapeutics (RLAY), Septerna (SEPN), Sana Biotechnology (SANA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Dianthus Therapeutics Upstream Bio Amphastar Pharmaceuticals LENZ Therapeutics Praxis Precision Medicines ARS Pharmaceuticals Relay Therapeutics Septerna Sana Biotechnology Collegium Pharmaceutical Dianthus Therapeutics (NASDAQ:DNTH) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Do insiders and institutionals believe in DNTH or KYTX? 47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 8.2% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is DNTH or KYTX more profitable? Kyverna Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-2,364.56% -34.72% -32.72% Kyverna Therapeutics N/A -64.98%-56.17% Which has more risk & volatility, DNTH or KYTX? Dianthus Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500. Do analysts recommend DNTH or KYTX? Dianthus Therapeutics currently has a consensus price target of $60.88, suggesting a potential upside of 82.97%. Kyverna Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 196.88%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has stronger earnings & valuation, DNTH or KYTX? Dianthus Therapeutics has higher earnings, but lower revenue than Kyverna Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M171.63-$84.97M-$3.25-10.24Kyverna Therapeutics$7.03M39.37-$127.48M-$3.68-1.74 Does the media refer more to DNTH or KYTX? In the previous week, Kyverna Therapeutics had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.69 beat Kyverna Therapeutics' score of 0.48 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDianthus Therapeutics beats Kyverna Therapeutics on 9 of the 16 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.80M$3.43B$6.17B$10.66BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-1.7423.4029.6328.51Price / Sales39.37477.72578.55129.15Price / CashN/A45.5937.1261.42Price / Book1.0410.3512.046.52Net Income-$127.48M-$52.53M$3.32B$276.75M7 Day Performance-8.70%-0.22%-0.16%0.20%1 Month Performance1.43%10.89%5.76%1.67%1 Year Performance28.26%14.19%65.69%32.72% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.9636 of 5 stars$6.40-4.0%$19.00+196.9%+28.3%$276.80M$7.03M-1.7496News CoverageGap UpDNTHDianthus Therapeutics2.5476 of 5 stars$34.52+0.3%$60.88+76.3%+19.8%$1.11B$6.24M-10.6380UPBUpstream Bio1.8454 of 5 stars$20.15+2.7%$53.33+164.7%-11.6%$1.11B$2.37M0.0038AMPHAmphastar Pharmaceuticals4.6851 of 5 stars$23.53+0.1%$31.60+34.3%-51.3%$1.09B$731.97M8.822,028News CoverageAnalyst ForecastLENZLENZ Therapeutics2.4432 of 5 stars$37.76-2.2%$52.80+39.8%+32.5%$1.08BN/A-19.95110Analyst ForecastPRAXPraxis Precision Medicines2.4209 of 5 stars$50.99-2.6%$85.56+67.8%+155.3%$1.08B$8.55M-4.16110Trending NewsAnalyst ForecastAnalyst RevisionSPRYARS Pharmaceuticals3.1455 of 5 stars$10.83-0.9%$33.80+212.1%-42.1%$1.07B$89.15M-22.1690RLAYRelay Therapeutics2.0239 of 5 stars$6.12-2.3%$16.50+169.4%-2.7%$1.05B$10.01M-3.13330SEPNSepterna1.7184 of 5 stars$23.43-2.7%$26.75+14.2%N/A$1.04B$1.08M-2.31N/ASANASana Biotechnology2.6654 of 5 stars$4.27-1.6%$7.50+75.7%+41.0%$1.02BN/A-4.04380COLLCollegium Pharmaceutical3.7385 of 5 stars$31.85-0.6%$42.33+32.9%-1.3%$1.01B$631.45M30.82210News Coverage Related Companies and Tools Related Companies DNTH Alternatives UPB Alternatives AMPH Alternatives LENZ Alternatives PRAX Alternatives SPRY Alternatives RLAY Alternatives SEPN Alternatives SANA Alternatives COLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYTX Stock Alerts